Market capitalization | $3.64b |
Enterprise Value | $12.01b |
P/E (TTM) P/E ratio | 4.24 |
EV/FCF (TTM) EV/FCF | 15.71 |
EV/Sales (TTM) EV/Sales | 1.88 |
P/S ratio (TTM) P/S ratio | 0.57 |
P/B ratio (TTM) P/B ratio | 7.72 |
Dividend yield | 7.93% |
Last dividend (FY24) | $1.12 |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
9 Analysts have issued a Organon & Co. forecast:
9 Analysts have issued a Organon & Co. forecast:
Dec '24 |
+/-
%
|
||
Revenue | 6,403 6,403 |
2%
2%
|
|
Gross Profit | 3,715 3,715 |
1%
1%
|
|
EBITDA | 1,770 1,770 |
13%
13%
|
EBIT (Operating Income) EBIT | 1,494 1,494 |
13%
13%
|
Net Profit | 864 864 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Organon & Co. is a science based global pharmaceutical company that develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020 and is headquartered in Jersey City, NJ.
Head office | United States |
CEO | Kevin Ali |
Employees | 10,000 |
Founded | 2020 |
Website | www.organon.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.